Kymera Therapeutics Appoints Dr. Elizabeth Laws To Lead KT-621 Development Program

Kymera Therapeutics, Inc. has appointed Dr. Elizabeth Laws as Senior Vice President and KT-621 Development Program Leader as the clinical-stage biopharmaceutical company advances the global development of its lead oral STAT6 degrader, KT-621. In her new role, Dr. Laws will oversee the strategy and worldwide development of the company's first-in-class investigational therapy, which is being evaluated for multiple immunological diseases.

Dr. Laws brings more than 20 years of experience in the biopharmaceutical industry, with expertise spanning research and development strategy, global clinical development, commercialization, launch planning, and franchise expansion. Before joining Kymera, she served as Senior Vice President and Head of Integrated Launch & Commercialization Excellence at Sanofi. She also held several senior leadership positions at the company, including Head of the Immunology and Inflammation Therapeutic Area and Head of the Dupilumab (Dupixent) Development Program, where she helped guide the global development and expansion of one of the industry's leading immunology therapies.

Announcing the appointment, Kymera Founder, President and Chief Executive Officer Dr. Nello Mainolfi said the company is entering a critical stage in the development of KT-621, with enrollment completed in its Phase IIb trial for atopic dermatitis, an ongoing Phase IIb asthma study, and preparations underway for registrational studies across multiple indications. He said Dr. Laws' extensive experience in immunology, clinical development, and commercialization will strengthen the company's efforts to advance KT-621 as a potential oral treatment for a range of Type 2 inflammatory diseases.

Commenting on her appointment, Dr. Laws said targeted protein degradation has the potential to address important unmet needs in the treatment of immunological diseases. She added that she looks forward to working with Kymera's scientific and clinical teams to advance the company's pipeline and help bring a new generation of oral immunology medicines to patients worldwide.

Earlier in her career, Dr. Laws held leadership positions in research operations, strategic planning, and alliance management at Sanofi, served as Vice President and Chief of Project Operations at MDS Pharma, and worked as a consultant in McKinsey & Company's Pharmaceuticals & Medical Products Practice. She was named one of Endpoints News' Top 20 Women Leading Biopharma R&D in 2023 and holds a PhD in Chemistry from the University of California, Berkeley, along with bachelor's degrees in Chemistry and Mathematics from Williams College.